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Figure 1. Regulation and function of transducers of regulated CREB activity (TORCs)
TORC proteins (yellow ovals) interact with the leucine zipper domain of CREB and help to recruit the coactiva-
tor TAFII130 and thereby stimulates transcription. TORC2 stimulates the expression of PGC-1α, which acts
downstream to help stimulate the expression of the PEPCK, G6Pase, and salt-inducible kinase 1 (SIK1).
Phosphorylation of Ser133 in CREB recruits the CREB binding protein (CBP) coactivator through interaction
with the Kix domain, and phosphorylation of several sites in CBP modulates transactivation by CREB. The
phosphorylation of TORCs by SIKs and AMPK promotes its cytoplasmic localization and suppresses gene
transactivation. cAMP enhances the phosphorylation of SIKs and suppresses their function; this can result in
decreased phosphorylation of TORCs and thereby promotes their translocation to the nucleus and association
with CREB. Insulin may limit the function of TORCs by promoting their phosphorylation and thereby antago-
nize the ability of cAMP to stimulate gene expression.
resistin and adiponectin, that stimulate
AMPK activity and suppress gluconeo-
genesis in the liver.
These studies provide important in-
sights into the mechanisms regulating
gluconeogenesis through CREB. TORC
proteins are also likely to be important in
the regulation of other metabolic path-
ways by CREB, and in settings where
CREB may contribute to the regulation
of cellular proliferation, including β cells
(Screaton et al., 2004) and in certain neo-
plasias (Conkright and Montminy, 2005).
Other factors, including FoxO proteins,
have recently received attention in medi-
ating early events in the regulation of glu-
coneogenic gene expression (Barthel et
al., 2005). The identification of TORCs as
mediators of hormone-regulated gluco-
neogenesis, and of the specific kinases
that regulate TORC phosphorylation and
function, are important advances in this
area of metabolism and may provide
new targets for the treatment of dia-
betes.
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The secondary complications of diabetes are the major factors limiting quality of life and longevity in diabetic patients.
Among these complications, cardiovascular disease is the major cause of morbidity and mortality. Based on a recent
paper by Vikramadithyan et al. (2005), this preview addresses the role of aldose reductase as a contributor to the patho-
genesis of diabetic macrovascular disease.212 CELL METABOLISM : OCTOBER 2005
P R E V I E W SDiabetes begins as a disturbance in glu-
cose metabolism, due to deficiency of or
resistance to the action of insulin, and
expands to a disorder affecting virtually
every tissue. It is the complications of
diabetes that ultimately have the great-
est impact on morbidity and mortality for
patients. Some of these complications,
such as retinopathy and nephropathy,
have been linked by clinical/epidemio-
logic studies more closely to control of
blood sugar (Duckworth et al., 2001;
Stratton et al., 2000). While other compli-
cations, such as accelerated atheroscle-
rosis in the setting of diabetes, are less
closely linked to blood sugar levels, sug-
gesting the contribution of additional fac-
tors underlying its pathogenesis (Duck-
worth et al., 2001; Stratton et al., 2000).
Macrovascular disease in the context
of diabetes is of considerable clinical
significance in view of increased mortal-
ity of diabetic patients subject to myo-
cardial infarction (Sprafka et al., 1991)
and the enhanced restenotic pathology
observed after balloon angioplasty/stent-
ing (Elezi et al., 1998). It has been some-
what difficult to develop robust models
of diabetic complications in mice, espe-
cially in the context of macrovascular
disease. Studies in genetically manipu-
lated, atherosclerosis-prone mice have
shown accelerated atherosclerosis, though
most often in the context of exaggerated
hyperlipidemia (Keren et al., 2000; Park
et al., 1998) Multiple studies using a
range of genetically manipulated mice
bred onto different backgrounds have
shown a full spectrum of variable results
with respect to the impact of diabetes
on atherosclerosis in murine models.
Taken together, these observations are
consistent with the absence of factors
permissive for the development in mice
of atherosclerosis, which, by contrast,
appears to occur quite easily in humans.
In the September issue of the Journal
of Clinical Investigation, work by Vikra-
madithyan et al. (Vikramadithyan et al.,
2005) adds an important piece to the
puzzle of diabetic macrovascular dis-
ease. The investigators identify aldose
reductase (AR), an enzyme involved in
the polyol pathway of glucose metabo-
lism (Brownlee, 2001) (Figure 1), as a
gene whose expression is quite low in
vascular tissue from mice, compared
with humans. They propose that restora-
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mCELL METABOLISM : OCTOBER 2005igure 1. A schematic depiction of hyperglycemia-initiated mechanisms underlying vascular complications
hile vascular endothelial cells are a major target of hyperglycemia-induced cell stress, macrophages and
ascular smooth muscle cells contribute to the pathogenesis of the vascular complications. The common
enominator of diabetic vascular disease appears to be a shift in the balance of pro- and antioxidant mecha-
isms in the vessel wall to favor oxidant stress (i.e., generation of ROS), thereby perturbing multiple down-
tream effector pathways essential for vascular homeostasis. Hyperglycemia induces the generation of ROS,
ia multiple pathways, including the AR-mediated polyol pathway, AGE-RAGE-induced signaling, diacylglyc-
rol (DAG) activation of the PKC pathway, and mitochondrial-dependent mechanisms. Multiple downstream
ffectors of ROS, such as activation of NF-kB with induction of proinflammatory/procoagulant gene expres-
ion, production of vascular endothelial growth factor, and quenching of nitric oxide, have the potential to
nduce vascular dysfunction leading to vascular complications.ion of AR levels in mice, using a human
R transgene (hAR) expressed broadly
nder control of the MHC class I pro-
oter (Yamaoka et al., 1995), will more
aithfully simulate the situation in human
acrovasculature. Thus, induction of
h
l
g
p
s
myperglycemia in the setting of elevated
evels of AR might accentuate vascular
lucose toxicity. The atherosclerosis-
rone murine system selected for these
tudies is the LDL receptor null mouse
odel.213
P R E V I E W SThe results of Vikramadithyan et al.
contribute valuable additional informa-
tion to murine models of diabetic com-
plications. First, they confirm in another
murine model that diabetes exacerbates
macrovascular disease. Second, they
show that the presence of the hAR
transgene further amplifies atherosclero-
sis in diabetic LDL receptor-deficient
homozygous and heterozygous mice
(the latter provided a system in which
plasma lipid profiles could be con-
trolled). The presence of diabetes is re-
quired for the hAR transgene to exert its
effect. Thus, these data confirm the au-
thors’ initial hypothesis, that increased
expression of AR in the mouse (but only
to levels that simulate the human milieu)
renders macrovasculature more suscep-
tible to the atherosclerotic process in the
presence of diabetes. They also provide
a genetically defined model focusing on
one pathogenic molecule, AR, in the
context of diabetic macrovascular dis-
ease. As always, there are multiple is-
sues that warrant further study and that
will ultimately determine how valuable
the new model is: While the observed
changes are statistically significant, will
they be sufficiently robust to be repro-
ducible across multiple laboratories?
Will the observed atherosclerosis not
only be more severe centrally but also
extend to the peripheral arterial tree and
be associated with changes in the mi-
crovasculature as well? Will this murine
model system be useful for providing
more faithful models of human compli-
cations applicable to other tissues, such
as nephropathy, neuropathy, and reti-
nopathy, all of which have proved diffi-
cult to evoke in mice? Another issue
concerns the high level of hAR expres-
sion in macrophages in the atheroscler-
otic lesions, suggesting a role for inflam-
matory events in the contribution of AR
to macrovascular lesions.
What do we know about mechanisms
underlying diabetic vascular disease and
how does the current work move the
field ahead? Changes in the redox state
of the vasculature, tilting the balance to-
ward oxidant stress, are associated with
a proatherogenic phenotype in a number
of situations (Figure 1). Generation of
oxidant stress occurs both through in-
creased production of/exposure to oxi-
dants, as well as via impaired antioxi-
dant defenses. The balance of pro- and
antioxidant mechanisms must be care-
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s214ully controlled, as transient and tightly
egulated generation of low levels of free
adicals is integral to homeostatic mech-
nisms. When oxidant processes domi-
ate in pathologic situations, the ensu-
ng host response involves activation of
yriad signaling and effector mecha-
isms (i.e., processes not activated as a
art of homeostatic signaling pathways),
rom activation of the cell death ma-
hinery to specific events, such as
uclear translocation of NF-kB with in-
uction of proinflammatory (and other)
ene families, production of vascular en-
othelial growth factor (a mediator of
ascular permeability and angiogenesis),
nd quenching of nitric oxide. In diabe-
es, glucose itself has oxidant proper-
ies, and the products of nonenzymatic
lycoxidation (termed advanced glyca-
ion endproducts or AGEs) have been
hown, in certain cases, to produce re-
ctive oxygen species directly, or follow-
ng their interaction with cellular sur-
aces (Baynes and Thorpe, 2000) (Figure
). In the latter case, binding of AGEs to
he immunoglobulin superfamily recep-
or RAGE (receptor for AGE) is associ-
ted with generation of reactive oxygen
pecies and an inflammatory cellular phe-
otype (Bierhaus et al., 2005). High levels
f glucose are also associated with acti-
ation of the protein kinase C pathways
Ahmad et al., 2005), resulting in far-
anging effects on cellular properties in-
luding barrier function of the endothe-
ial cell layer.
Enhanced glucose metabolism via the
olyol pathway, leading to production of
orbitol, which is oxidized to fructose,
its into this complex scheme of oxidant
ell stress (Vincent et al., 2004) (Figure
). High levels of AR activity can dimin-
sh reduced glutathione, probably via
epletion of NADPH. Regeneration of
he pool of reduced glutathione and
aintenance of NADPH levels are es-
ential for oxidant-antioxidant homeo-
tatic balance. An intracellular environ-
ent favoring generation of oxidants
an lead to production of reactive dicar-
onyls, the key element in the formation
f Advanced Glycation End products or
GEs (Baynes and Thorpe, 2000). The
bserved increased levels of glutathione
eroxidase (a mitochondrial enzyme), as
ell as glucose-6-phosphate dehydro-
enase (in the cytosol), observed by Vik-
amadithyan et al. suggest oxidant stress
ensed throughout the cell. In this con-
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eext, diabetes/high glucose is also asso-
iated with increased electron flux from
he tricarboxylic acid cycle (via FADH2-
ADH) into mitochondria with exag-
erated leakage of mitochondrial ROS
Brownlee, 2001). RAGE-mediated sig-
aling also involves several intracellu-
ar pathways at the level of NADPH oxi-
ase and mitochondria leading to ROS
eneration. Thus, taken together with
R-induced impairment of antioxidant
athways (availability of NADPH and re-
uced glutathione), the scene is set for
ccentuated oxidant stress. The plot
rows more complex as aspects of the
ellular response to such stress result in
ncreased uptake of modified lipopro-
eins (due to increased expression of
ertain scavenger receptors on macro-
hages, as shown by Vikramadithyan et
l.) and expression of inflammatory me-
iators.
As always, there are potentially many
mportant contributors to the pathogen-
sis of a complex disorder such as dia-
etic macrovascular disease. Modulation
f oxidant stress, and its accompanying
nflammatory response, especially in tar-
eting factors prevalent in the diabetic
ascular environment, would be a logical
ocus in the search for therapeutic
gents. In this context, the work of Vik-
amadithyan et al. certainly adds cre-
ence to a possible beneficial action of
R inhibitors in diabetic macrovascular
isease. However, multiple factors may
e capable of tipping the balance of oxi-
ant and inflammatory stress towards
herapeutic benefit and, thereby, block-
ng the impact of increased levels of AR
provided these are indeed the principal
eans through which AR exerts its ef-
ects) and other factors in the diabetic mi-
roenvironment. For example, decreasing
roduction of intracellular glucotoxins
y enhancing activity of glyoxalase I,
eroxisome proliferator activated recep-
or agonists, 12/15-lipoxygenase antag-
nists, antioxidants (alpha-lipoic acid,
tc.), RAGE antagonists, protein kinase
inhibitors, and so on are likely to have
beneficial effect in the diabetic trans-
enic hAR/LDL receptor null model pre-
ented by Vikramadithyan. Thus, the “sun
as not set” on the important problem
f diabetic macrovascular disease, but
e seem to be edging towards an un-
erstanding of pathogenic mechanisms in
manner that should soon lead to more
ffective therapeutic approaches.CELL METABOLISM : OCTOBER 2005
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